Keywords: Sanofi, Lyxumia, Lixisenaatide, Type 2 diabetes, Zealand Pharma, Ph III

Positive Ph III results from Sanofi GetGoal Program on Lyxumia

Article | 01 June 2011

Print This

French drug major Sanofi (Euronext: SAN) announced today that new results from a Phase III study showed that the investigational ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in